These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27891815)

  • 41. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
    Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contrast-enhanced MR Imaging versus Contrast-enhanced US: A Comparison in Glioblastoma Surgery by Using Intraoperative Fusion Imaging.
    Prada F; Vitale V; Del Bene M; Boffano C; Sconfienza LM; Pinzi V; Mauri G; Solbiati L; Sakas G; Kolev V; D'Incerti L; DiMeco F
    Radiology; 2017 Oct; 285(1):242-249. PubMed ID: 28562204
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
    Ellingson BM; Wen PY; Cloughesy TF
    Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
    Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imaging of Primary Brain Tumors and Metastases with Fast Quantitative 3-Dimensional Magnetization Transfer.
    Garcia M; Gloor M; Bieri O; Radue EW; Lieb JM; Cordier D; Stippich C
    J Neuroimaging; 2015; 25(6):1007-14. PubMed ID: 25702714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
    Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
    Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.
    Cordova JS; Shu HK; Liang Z; Gurbani SS; Cooper LA; Holder CA; Olson JJ; Kairdolf B; Schreibmann E; Neill SG; Hadjipanayis CG; Shim H
    Neuro Oncol; 2016 Aug; 18(8):1180-9. PubMed ID: 26984746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
    Prah MA; Al-Gizawiy MM; Mueller WM; Cochran EJ; Hoffmann RG; Connelly JM; Schmainda KM
    J Neurooncol; 2018 Jan; 136(1):13-21. PubMed ID: 28900832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Accuracy of High-Field Intraoperative MRI in the Detectability of Residual Tumor in Glioma Grade IV Resections.
    Heßelmann V; Mager AK; Goetz C; Detsch O; Theisgen HK; Friese M; Schwindt W; Gottschalk J; Kremer P
    Rofo; 2017 Jun; 189(6):519-526. PubMed ID: 28591887
    [No Abstract]   [Full Text] [Related]  

  • 50. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.
    Li Y; Lupo JM; Polley MY; Crane JC; Bian W; Cha S; Chang S; Nelson SJ
    Neuro Oncol; 2011 May; 13(5):546-57. PubMed ID: 21297128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.
    Cui Y; Ren S; Tha KK; Wu J; Shirato H; Li R
    Eur Radiol; 2017 Sep; 27(9):3583-3592. PubMed ID: 28168370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma.
    Gzell CE; Wheeler HR; McCloud P; Kastelan M; Back M
    J Neurooncol; 2016 May; 128(1):67-74. PubMed ID: 26879084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI.
    Bisdas S; Smrdel U; Bajrovic FF; Surlan-Popovic K
    Clin Neuroradiol; 2016 Mar; 26(1):39-45. PubMed ID: 25164691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.
    Schmainda KM; Prah MA; Zhang Z; Snyder BS; Rand SD; Jensen TR; Barboriak DP; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Jul; 40(7):1132-1139. PubMed ID: 31248863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
    Yao J; Tan CHP; Schlossman J; Chakhoyan A; Raymond C; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2019 May; 142(3):587-595. PubMed ID: 30806888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences between primary central nervous system lymphoma and glioblastoma: topographic analysis using voxel-based morphometry.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Hata N; Akagi Y; Suzuki SO; Iwaki T; Iihara K; Honda H
    Clin Radiol; 2019 Oct; 74(10):816.e1-816.e8. PubMed ID: 31400805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.
    Li C; Wang S; Serra A; Torheim T; Yan JL; Boonzaier NR; Huang Y; Matys T; McLean MA; Markowetz F; Price SJ
    Eur Radiol; 2019 Sep; 29(9):4718-4729. PubMed ID: 30707277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.